Lymphoma Clinical Trials

88 studies are recruiting for lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

   "This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic patients with solid tumor malignancies receiving SBRT. CD8+ T cells are …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05371132 on ClinicalTrials.gov

2. Mosaic Trial for Stem Cell Transplant Recipients

   The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Georgetown University School of Medicine, Washington D.C., District of Columbia

   Locations

   3 in total

   Run by

   Northwestern University

   See if you can join NCT06960993 on ClinicalTrials.gov

3. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

   Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and le…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03223610 on ClinicalTrials.gov

4. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   6 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

5. Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

   This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. R…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07583810 on ClinicalTrials.gov

6. Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

   RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic c…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT01137643 on ClinicalTrials.gov

7. A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

   The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   5 in total

   Run by

   Spectrum Pharmaceuticals, Inc

   See if you can join NCT04570423 on ClinicalTrials.gov

8. HEME Home Transfusion Program

   This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06487247 on ClinicalTrials.gov

9. Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

   This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

   Stage

   EARLY_Phase 1

   Ages

   18 to 99

   Site

   Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   2 in total

   Run by

   University of Oklahoma

   See if you can join NCT05921253 on ClinicalTrials.gov

10. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

    Stage

    Phase 1

    Ages

    2 to 18

    Site

    Lucile Packard Children's Hospital at Stanford, Palo Alto, California

    Locations

    9 in total

    Run by

    ITM Solucin GmbH

    See if you can join NCT06441331 on ClinicalTrials.gov

11. Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

    Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically in…

    Stage

    Not phased

    Ages

    5 and older

    Site

    Children s Hospital of Los Angeles, Los Angeles, California

    Locations

    3 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05237986 on ClinicalTrials.gov

12. A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

    The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center, Miami, Florida

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT07013435 on ClinicalTrials.gov

13. Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

    The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cau…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT02974647 on ClinicalTrials.gov

14. Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

    This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: * Pembrolizumab (a type of monoclonal antibody) * M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06475235 on ClinicalTrials.gov

15. GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

    The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphomas. This clinical trial also aims to investigate other efficacy pa…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT07711483 on ClinicalTrials.gov

16. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

    Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To o…

    Stage

    Not phased

    Ages

    3 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT01441089 on ClinicalTrials.gov

17. Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

    Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03258567 on ClinicalTrials.gov

18. Sample Collection and Tracking for the Developmental Therapeutics Clinic

    Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. R…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03269578 on ClinicalTrials.gov

19. Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

    The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Sylvester Comprehensive Cancer Center, Miami, Florida

    Locations

    3 in total

    Run by

    University of Miami

    See if you can join NCT05745285 on ClinicalTrials.gov

20. Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

    The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York

    Locations

    2 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05940272 on ClinicalTrials.gov

21. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

    This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Research Site, Duarte, California

    Locations

    38 in total

    Run by

    AstraZeneca

    See if you can join NCT06137144 on ClinicalTrials.gov

22. An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

    The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve ta…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07226934 on ClinicalTrials.gov

23. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    City of Hope Cancer Center, Duarte, California

    Locations

    83 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT06084936 on ClinicalTrials.gov

24. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06398457 on ClinicalTrials.gov

25. A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

    To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06563505 on ClinicalTrials.gov